JP2018510219A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510219A5 JP2018510219A5 JP2018500271A JP2018500271A JP2018510219A5 JP 2018510219 A5 JP2018510219 A5 JP 2018510219A5 JP 2018500271 A JP2018500271 A JP 2018500271A JP 2018500271 A JP2018500271 A JP 2018500271A JP 2018510219 A5 JP2018510219 A5 JP 2018510219A5
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- sequence
- nucleic acid
- acid sequence
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000725303 Human immunodeficiency virus Species 0.000 claims 45
- 150000007523 nucleic acids Chemical group 0.000 claims 28
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 108091033409 CRISPR Proteins 0.000 claims 20
- 238000010354 CRISPR gene editing Methods 0.000 claims 13
- 108010042407 Endonucleases Proteins 0.000 claims 12
- 102000004533 Endonucleases Human genes 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- 108020005004 Guide RNA Proteins 0.000 claims 9
- 239000013598 vector Substances 0.000 claims 9
- 239000013604 expression vector Substances 0.000 claims 8
- 108091027981 Response element Proteins 0.000 claims 6
- 108091026890 Coding region Proteins 0.000 claims 5
- 108091092724 Noncoding DNA Proteins 0.000 claims 5
- 108091081548 Palindromic sequence Proteins 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 108091032955 Bacterial small RNA Proteins 0.000 claims 4
- 239000003623 enhancer Substances 0.000 claims 4
- 210000005260 human cell Anatomy 0.000 claims 4
- 239000013603 viral vector Substances 0.000 claims 4
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 210000004962 mammalian cell Anatomy 0.000 claims 3
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- 239000000084 colloidal system Substances 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 208000032420 Latent Infection Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 210000000274 microglia Anatomy 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562136080P | 2015-03-20 | 2015-03-20 | |
| US62/136,080 | 2015-03-20 | ||
| PCT/US2016/023170 WO2016154016A2 (en) | 2015-03-20 | 2016-03-18 | Tat-induced crispr/endonuclease-based gene editing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018510219A JP2018510219A (ja) | 2018-04-12 |
| JP2018510219A5 true JP2018510219A5 (https=) | 2019-04-25 |
Family
ID=56979180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018500271A Pending JP2018510219A (ja) | 2015-03-20 | 2016-03-18 | Ｔａｔ誘導性ｃｒｉｓｐｒ／エンドヌクレアーゼに基づく遺伝子編集 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20180073019A1 (https=) |
| EP (1) | EP3271021A4 (https=) |
| JP (1) | JP2018510219A (https=) |
| KR (1) | KR20170137114A (https=) |
| CN (1) | CN107949424B (https=) |
| AU (1) | AU2016235472A1 (https=) |
| BR (1) | BR112017019966A2 (https=) |
| CA (1) | CA2980317A1 (https=) |
| EA (1) | EA201792092A1 (https=) |
| HK (1) | HK1254230A1 (https=) |
| IL (1) | IL254480A0 (https=) |
| MA (1) | MA41382A (https=) |
| MX (1) | MX2017011829A (https=) |
| SG (2) | SG10201908773UA (https=) |
| WO (1) | WO2016154016A2 (https=) |
| ZA (1) | ZA201706236B (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| CN108513580A (zh) | 2015-10-08 | 2018-09-07 | 哈佛学院董事及会员团体 | 多重基因组编辑 |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| CA3026332A1 (en) * | 2016-06-03 | 2017-12-14 | Temple University - Of The Commonwealth System Of Higher Education | Negative feedback regulation of hiv-1 by gene editing strategy |
| CN110214183A (zh) | 2016-08-03 | 2019-09-06 | 哈佛大学的校长及成员们 | 腺苷核碱基编辑器及其用途 |
| WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| KR102622411B1 (ko) | 2016-10-14 | 2024-01-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| US20200140865A1 (en) * | 2017-04-17 | 2020-05-07 | Temple University - Of The Commonwealth System Of Higher Education | An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents |
| KR102746223B1 (ko) | 2017-04-20 | 2024-12-27 | 이제네시스, 인크. | 유전자 변형 동물의 생성 방법 |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| CN108559730B (zh) * | 2018-01-12 | 2021-09-24 | 中国人民解放军第四军医大学 | 利用CRISPR/Cas9技术构建Hutat2:Fc基因敲入单核细胞的实验方法 |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| US12410428B2 (en) * | 2018-10-18 | 2025-09-09 | University Of Utah Research Foundation | RNA-guided transcriptional regulation and methods of using the same for the treatment of back pain |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| JP2022511508A (ja) * | 2018-12-04 | 2022-01-31 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | ゲノム編集による遺伝子サイレンシング |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| EP3918071A1 (en) * | 2019-02-01 | 2021-12-08 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions targeting virus genomes |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| IL297761A (en) | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence |
| US11643672B2 (en) * | 2021-10-01 | 2023-05-09 | The Florida International University Board Of Trusters | Inducible CRISPR system expression and applications thereof |
| CN119372255A (zh) * | 2023-07-27 | 2025-01-28 | 中国科学院武汉病毒研究所 | 一种重组病毒载体及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5306631A (en) * | 1987-08-21 | 1994-04-26 | University Of Colorado Foundation, Inc. | Compositions and method for inhibition of HIV production |
| US5693508A (en) * | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
| US5853716A (en) * | 1995-07-28 | 1998-12-29 | Yale University | Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators |
| EP1003894A2 (en) * | 1997-07-18 | 2000-05-31 | Chiron Corporation | Lentiviral vectors |
| FR2893631A1 (fr) * | 2005-11-21 | 2007-05-25 | Chu Nice | Promoteurs inductibles |
| EP2120562A4 (en) * | 2006-11-21 | 2010-01-13 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR TREATING HIV INFECTIONS |
| RU2012140691A (ru) * | 2009-03-13 | 2014-03-27 | Лентиген Корпорейшен | Вакцины на основе неинтегрирующегося ретровирусного вектора |
| CA2908253C (en) * | 2013-04-04 | 2024-01-09 | Trustees Of Dartmouth College | Compositions and methods for in vivo excision of hiv-1 proviral dna |
| JP7118588B2 (ja) * | 2013-08-29 | 2022-08-16 | テンプル ユニヴァーシティ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Ｈｉｖ感染のｒｎａガイド処置のための方法および組成物 |
| CN104263745B (zh) * | 2014-09-16 | 2017-06-09 | 中国医学科学院医学实验动物研究所 | 一种重组免疫缺陷质粒和病毒以及应用 |
-
2016
- 2016-03-17 MA MA041382A patent/MA41382A/fr unknown
- 2016-03-18 EA EA201792092A patent/EA201792092A1/ru unknown
- 2016-03-18 CN CN201680029128.8A patent/CN107949424B/zh active Active
- 2016-03-18 SG SG10201908773U patent/SG10201908773UA/en unknown
- 2016-03-18 KR KR1020177030267A patent/KR20170137114A/ko not_active Withdrawn
- 2016-03-18 JP JP2018500271A patent/JP2018510219A/ja active Pending
- 2016-03-18 WO PCT/US2016/023170 patent/WO2016154016A2/en not_active Ceased
- 2016-03-18 SG SG11201707458VA patent/SG11201707458VA/en unknown
- 2016-03-18 AU AU2016235472A patent/AU2016235472A1/en not_active Abandoned
- 2016-03-18 US US15/559,902 patent/US20180073019A1/en not_active Abandoned
- 2016-03-18 HK HK18113373.0A patent/HK1254230A1/zh unknown
- 2016-03-18 EP EP16769422.3A patent/EP3271021A4/en not_active Withdrawn
- 2016-03-18 CA CA2980317A patent/CA2980317A1/en not_active Abandoned
- 2016-03-18 BR BR112017019966-1A patent/BR112017019966A2/en not_active IP Right Cessation
- 2016-03-18 MX MX2017011829A patent/MX2017011829A/es unknown
-
2017
- 2017-09-13 ZA ZA2017/06236A patent/ZA201706236B/en unknown
- 2017-09-13 IL IL254480A patent/IL254480A0/en unknown
-
2022
- 2022-07-15 US US17/866,261 patent/US20230193257A1/en not_active Abandoned
-
2024
- 2024-09-26 US US18/897,253 patent/US20250250562A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510219A5 (https=) | ||
| Bobbin et al. | RNA interference approaches for treatment of HIV-1 infection | |
| JP2016534125A5 (https=) | ||
| US20220313795A1 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
| US20190032057A1 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
| AU2017219605B2 (en) | Excision of retroviral nucleic acid sequences | |
| US11566237B2 (en) | Silencing of DUX4 by recombinant gene editing complexes | |
| Al-Allaf et al. | LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives | |
| CN107949424A (zh) | Tat诱导的基于crispr/核酸内切酶的基因编辑 | |
| WO2017213896A1 (en) | Negative feedback regulation of hiv-1 by gene editing strategy | |
| WO2018194876A1 (en) | An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents | |
| Weber et al. | Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects | |
| Guan et al. | How Advanced are Nanocarriers for Effective Subretinal Injection? | |
| Saha et al. | Advancements in modern biotechnological approaches for combating HIV infection | |
| Chiru et al. | Delivering the" Blueprints" or" DNA Repairing Kits" Instead of Drugs in the Treatment of Congenital Hemoglobinopathies | |
| HK40114560A (en) | Methods and compositions for rna-guided treatment of hiv infection | |
| HK40000290A (en) | Excision of retroviral nucleic acid sequences |